Solbec is a very promising emerging biotech with the potential...

Solbec is a very promising emerging biotech with the potential to treat a very broad range of cancers.

SBP is expected to be given the go-ahead for its Phase 1 human trials to commence at any time now.

SBP's SBP002 is a naturally derived substance, that has been shown to actively pursue and be effective on all cancer types it has been tested upon, yet is relatively non-toxic to normal cells and has had success on numerous humans(in various individual cases).

SBP002 also appears to boost the immune system of the recipient patient and has significant diagnostic potential.

With a market cap. of less than $30m, SBP offers multiple potential returns and has momentum now